What is Daye?
Headquartered in London, Daye operates on a monthly subscription model, delivering sustainable and organic period care products directly to consumers. The company's offerings include standard and CBD-infused tampons, alongside 'ProViotics' aimed at enhancing vaginal health. Beyond its product line, Daye is actively engaged in initiatives to address gender biases within medical research and product innovation, positioning itself as a socially conscious entity in the health and wellness sector. The company's focus on sustainable and innovative period care solutions targets a growing market segment increasingly prioritizing ethical and health-conscious consumption.
How much funding has Daye raised?
Daye has raised a total of $11.5M across 1 funding round:
Series A
$11.5M
Series A (2022): $11.5M with participation from Hambro Perks, Cross-Border Impact Ventures, and MassMutual Ventures
Key Investors in Daye
Hambro Perks
Hambro Perks is an international investment firm specializing in private technology, supporting growth businesses across various stages of the investment cycle with dedicated teams and differentiated investment strategies.
Cross-Border Impact Ventures
Cross-Border Impact Ventures is an impact venture capital firm focused on transformative health technology companies, particularly in women's, children's, and adolescent health, aiming for both social impact and financial returns.
MassMutual Ventures
MassMutual Ventures is an investor in Daye's funding round, contributing to the company's strategic growth initiatives.
What's next for Daye?
With the recent major strategic investment, Daye is poised for accelerated expansion. This capital injection will likely fuel further product development, enhance its subscription service infrastructure, and broaden its market reach, both domestically and internationally. The company's commitment to tackling gender biases in medical research suggests a strategic focus on long-term impact, potentially leading to new research partnerships and the development of novel health solutions. Daye's trajectory indicates a company moving into a scaling phase, leveraging its established subscription model and brand reputation to capture a larger share of the global femtech market.
See full Daye company page
